662 results found | searching for "anti"
-
-
Greenlam AFX Laminates – Elegant, Easy‑Clean & Anti‑Virus Surface Discover Greenlam AFX Laminates—ultra-matt, anti-fingerprint, and easy-to-clean surfaces designed for modern interiors. With anti-virus, anti-bacterial, and scratch-resistant properties, these laminates combine elegance and hygiene, making them perfect for both residential and commercial spaces. Visit: https://www.greenlam.co.in/afx/ #laminates
-
-
Hydac Stat-Free Series Anti-Static Cartridge Filter Elements Eliminate static discharge and improve system safety with Hydac Stat-Free Series Anti-Static Filter Elements. Easy to install and maintain. Order now. https://www.pwrfs.com/product/hydac-stat-free-series-anti-static-cartridge-filter-elements/ #HydacStatFreeSeriesAntiStaticCartridgeFilterElements #HydacAntiStaticCartridgeFilterElements #HydacStatFreeSeriesFilterCartridges -
-
How to Remove Acne Scars Naturally in a Week Removing acne scars naturally within a week is difficult, but using honey, aloe vera, or lemon juice may help diminish scars over time. For effective and safe results, consult a dermatologist about personalized treatment options. Acne scars are the marks left by chronic acne after it has cleared. According to estimates, one out of every five people with acne has acne scars. These appear on the face, back, and chest area. You can repair your acne scars naturally or with medicated cosmetic treatments from a reputable facility such as MedLinks. The latter comprises salicylic acid peels, acne treatments, microneedling, and fractional CO2 resurfacing. All of these operations necessitate expert care and patience. For those who prefer a natural approach, this article will provide how to remove acne scar naturally. MedLinks Aesthetics, is one of the best dermatologist in Delhi and Gurgaon, offering skin treatment in Delhi. He specializes in clinical and cosmetic dermatology and offers services such as acne treatment, anti-aging therapies, and hair restoration, ensuring personalized care for optimal patient satisfaction. https://www.medlinks.in/blog/how-to-remove-acne-scars-naturally-in-a-week -
-
Restore Vision with Stem Cell Therapy For Age Related Macular Degeneration (AMD) Stem cell therapy is a potential alternative for AMD treatment. Its ability to regenerate has been used to treat a variety of illnesses with positive results. Mesenchymal stem cells have exhibited therapeutic properties such as anti-inflammation, angiogenesis, cell regeneration, and antioxidant properties that can prove beneficial in AMD due to their related mechanisms. Therefore, stem cells were employed for AMD treatment. The initial studies have shown favorable outcomes but require additional research. Clinical trials with large sample sizes and longer time periods will provide a better assessment of the therapy. Additionally, the treatment requires extensive standardization regarding administration route and dosage. Scientists are also exploring gene therapy and Mesenchymal stem cells derived retinal cells to maximize the potential of the therapy. Advancells is nurturing the growth of stem cell therapy for eyes in India by delivering premium-quality stem cells. Read more-https://shorturl.at/mFM6o
-
-
Laser Hair Reduction in Delhi at MedLinks Aesthetics MedLinks is your go-to laser hair reduction in Delhi, offering clients permanent hair removal solutions. Our staff includes professional dermatologists who use the most recent laser hair removal techniques. As one of the leading skin clinics in Delhi, we offer painless laser therapies that produce the greatest results for smooth and hair-free skin. Dr. Pankaj Chaturvedi, co-founder of MedLinks Aesthetics, is a leading dermatologist in Delhi and Gurgaon, providing innovative skin and hair treatments. With expertise in clinical and cosmetic dermatology, he offers procedures such as acne treatment, anti-aging therapies, and hair restoration, assuring customized care and maximum patient satisfaction. Visit- https://www.medlinks.in/laser-hair-reduction-delhi/ -
-
Dr. Pankaj Chaturvedi Best Dermatologist In Gurgaon at MedLinks Aesthetics Dr. Pankaj Chaturvedi, co-founder of MedLinks Aesthetics, is best dermatologist in Gurgaon, providing innovative skin and hair treatments. With expertise in clinical and cosmetic dermatology, he offers procedures such as acne treatment, anti-aging therapies, and hair restoration, assuring customized care and maximum patient satisfaction. Dr. Pankaj Chaturvedi is an internationally recognized dermatologist who specializes in advanced skin and hair treatments. After graduating from the prestigious All India Institute of Medical Sciences (AIIMS) in New Delhi, he co-founded MedLinks, a cutting-edge clinic for skin treatment in Gurgaon. Because of his desire to provide more beautiful and natural-looking results for patients, he has invented a number of world-first non-surgical techniques that have won him an international reputation. Visit-- https://www.medlinks.in/best-dermatologist-in-gurgaon
-
-
Pharmaceutical Giants Rush to Develop PD-(L)1 Bispecific Antibodies: A New Battlefield in Immunotherapy In recent years, immune checkpoint inhibitors (ICIs) have emerged as a significant breakthrough in cancer therapy, reshaping traditional treatment paradigms. PD-1/PD-L1 pathway inhibitors have been widely used across various cancer treatments, demonstrating impressive efficacy. As PD-(L)1 inhibitor therapies continue to mature, pharmaceutical giants have turned their attention to PD-(L)1 bispecific antibodies (BsAbs), a new class of antibody drugs that has become a hot field for development in the industry. The key advantage of PD-(L)1 bispecific antibodies is their ability to target both PD-1 and PD-L1 simultaneously, not only enhancing anti-tumor activity through stronger immune activation effects but also overcoming the limitations of single-target antibodies. As a result, pharmaceutical companies have invested heavily in developing PD-(L)1 bispecific antibodies, striving to achieve breakthroughs in this area. PD-(L)1 bispecific antibodies are one of the brightest stars in antibody drug development. These bispecific antibodies can recognize two different antigens or targets at the same time, resulting in a synergistic effect. In their design, bispecific antibodies not only block the binding between PD-1 and PD-L1 but also recruit immune cells, enhancing the immune system's ability to attack tumors. This "two-pronged" strategy has made PD-(L)1 bispecific antibodies a focal point in cancer immunotherapy. Currently, numerous pharmaceutical and biotechnology companies are actively advancing the clinical research of PD-(L)1 bispecific antibodies, especially in cancer immunotherapy, where they show significant promise. Some PD-(L)1 bispecific antibodies can not only target immune evasion mechanisms within the tumor microenvironment but also significantly improve patient survival, positioning them as the "new favorite" in cancer immunotherapy. The PD-1/PD-L1 Pathway and Mechanism of Immune Escape PD-1 (Programmed Cell Death Protein 1) is a crucial checkpoint in the immune system. By binding to its ligand PD-L1, PD-1 inhibits T-cell activation, regulating immune responses and preventing excessive immune reactions that could harm the body's tissues. However, tumor cells often exploit this mechanism to evade immune surveillance, promoting their growth and metastasis. The role of the PD-1/PD-L1 pathway in immune evasion makes it a key target for immunotherapy. The application of PD-1 and PD-L1 monoclonal antibodies helps to relieve immune suppression, restore T-cell function, and boost the immune system's ability to recognize and eliminate tumor cells. As a result, immune checkpoint inhibitors are widely used in the treatment of various cancers, including non-small cell lung cancer, melanoma, and renal cell carcinoma. Despite the promising clinical efficacy of PD-1/PD-L1 inhibitors, challenges remain. Some patients develop resistance to these therapies, and side effects, such as immune-related adverse events, can complicate clinical application. This has driven researchers and pharmaceutical companies to explore new treatment options, with bispecific antibodies emerging as a promising solution. In the development of immunotherapy drugs, the use of cell models plays a critical role. Human PD-1 recombinant cell lines are among the most essential tools for studying the PD-1 pathway, widely used for drug screening, mechanistic research, and preclinical evaluation. By stably expressing the PD-1 protein in cells, researchers can simulate interactions between immune cells and tumor cells, explore the mechanisms of the PD-1/PD-L1 pathway, and evaluate the efficacy of PD-1/PD-L1 targeted therapies. For example, using these recombinant cell lines, researchers can simulate immune escape processes in the tumor microenvironment, investigate the mechanisms of action of PD-1 inhibitors, and screen new antibody drugs. This tool is also crucial in evaluating the preclinical potential of drugs, contributing to the advancement of anti-tumor immunotherapies. As the field of immunotherapy continues to evolve, the clinical application of PD-1/PD-L1 inhibitors has made significant strides. However, several challenges remain, particularly related to individual variation, resistance, and side effects. Researchers are actively exploring combination therapies to enhance treatment outcomes, such as combining PD-1 inhibitors with chemotherapy, targeted therapies, or vaccines. This may help overcome resistance and improve the overall efficacy of treatment. Furthermore, as new immunotherapy strategies emerge, the application of PD-1 and related treatments may extend beyond cancer. Immune checkpoint inhibitors are showing promise in autoimmune diseases, infectious diseases, and other areas, making them a key focus in future medical research. From the early days of single-target therapies to the current focus on bispecific antibodies, immunotherapy continues to innovate, transforming cancer treatment approaches. With the emergence of PD-1 recombinant cell lines and new immunotherapy solutions, we can look forward to a new era in cancer therapy, where more patients will benefit and the full potential of immunotherapy will be unlocked. https://www.creative-biolabs.com/immuno-oncology/human-pd-1-recombinant-cell-line-jurkat-2696.htm
-
-
New Insights Into the Pathogenesis and Diagnosis of Rheumatoid Arthritis The hallmark of rheumatoid arthritis (RA) is erosive arthritis, an autoimmune disease that ultimately results in joint deformities and functional loss. It can also be complicated by pulmonary disease, cardiovascular disease, malignant tumors, and depression. The etiology of RA remains unclear. However, infections have been suggested as environmental triggers in as many as 20% of patients. Due to its perplexing etiology, a more detailed exploration of the pathogenesis of RA has been presented in an article titled "Altered antibody response to Epstein-Barr virus in patients with rheumatoid arthritis and healthy subjects predisposed to the disease" published in Immunol. The article delves deeper into the potential connection between Epstein-Barr virus (EBV) and RA, employing dependable tests that quantify antibodies directed against specific EBV antigens. So why did the research team link EBV to the development of RA? A disease similar to RA called polyarticular arthritis is induced by various viral infections, including rubella, HTLV-1, parvovirus B19, etc. Given that EBV has been connected with other autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus, it is reasonable to assume that this virus may also be related to the pathogenesis of RA. Therefore, this article investigates the EBV antibody patterns in rheumatoid arthritis patients to assess the heritability of the antibody responses to the EBV-encoded EBNA1 protein, ultimately concluding that the levels of EBNA1 antibodies are notably dissimilar in RA patients compared to healthy individuals. Nevertheless, the findings reached in this article represent just a fraction of the complex investigation into the etiology of RA. Undoubtedly, the uncertain underlying causes of RA pose challenges for accurate diagnosis. RA can affect individuals of any age, but it is most frequently diagnosed in individuals between the ages of 35 and 50. Early diagnosis of RA can help identify people at risk of RA and prevent complications and disease progression. Modern imaging techniques, such as X-rays, magnetic resonance imaging, and ultrasound, aid in diagnosing RA by capturing images of affected joints. However, these methods are challenging for early RA diagnosis due to the similarity of early symptoms with those of other diseases. Additionally, detection methods that use serum markers, such as the anti-cyclic citrullinated peptide test in combination with rheumatoid factor, can improve the final diagnosis of patients with negative results from routine tests. As an efficient and precise method, IVD immunological assays and test kits rely on the specific recognition between one or more antibodies and an antigen, allowing for the detection and quantification of various antibodies in different types of samples (including serum, urine, saliva, environmental media, and more). Specifically, some rheumatoid arthritis biomarkers that have been developed for early diagnosis of RA include but are not limited to UH-RA 1, UH-RA 9, UH-RA 14, UH-RA 21, Rheumatoid Factor, 14-3-3 Eta Protein, PAD4, etc. Not only are RA biomarkers evolving, but so are their development solutions in the following approaches: * IVD Antibody Development * Antibody Pair Development * Antibody & Protein Conjugation * IVD Immunoassay Development https://www.creative-biolabs.com/drug-discovery/diagnostics/biomarker-and-antibody-development-for-rheumatoid-arthritis.htm
-
-
From IgE to IgA: New Antibody Frontiers in Allergen Immunotherapy Allergic diseases such as asthma and allergic rhinitis affect billions of people around the world, often reducing quality of life and straining healthcare systems. Traditional treatments—including antihistamines and corticosteroids—primarily aim to control symptoms, but they don’t address the underlying immune dysfunction that causes allergic reactions. This is where allergen immunotherapy (AIT) steps in, offering a more targeted and long-term solution. Among the cutting-edge approaches in this field is the development of non-IgG therapeutic antibodies, which are opening new avenues for treating allergic conditions. Understanding Allergen Immunotherapy Allergen immunotherapy is a biomedical approach designed to reprogram the immune system’s response to allergens. Instead of simply suppressing symptoms, AIT works by gradually desensitizing the immune system, allowing it to tolerate allergens that previously triggered severe reactions. This method has shown notable success in treating patients with moderate to severe allergic rhinitis and asthma, especially when traditional therapies fall short. The underlying mechanism of AIT is based on inducing immune tolerance. Key players in this process include immunoglobulins, the most relevant being IgE and IgA. These antibodies are involved in recognizing and responding to allergens, often in ways that lead to excessive immune reactions in allergic individuals. The Problem with IgE: Targeting the Culprit Among the various antibody types, Immunoglobulin E (IgE) is central to the development of allergic responses. When a person with an allergy is exposed to an allergen—be it pollen, pet dander, or dust mites—IgE binds to that allergen and triggers the release of inflammatory molecules such as histamine. This leads to classic allergy symptoms: sneezing, itching, wheezing, and in severe cases, anaphylaxis. Targeting IgE directly has become a logical therapeutic strategy. Anti-IgE antibodies can bind to free IgE in the bloodstream, reducing its ability to attach to immune cells and initiate allergic inflammation. Clinical use of anti-IgE therapy has demonstrated significant improvements in controlling allergic respiratory diseases. These therapies work by lowering circulating IgE levels and reducing the expression of its high-affinity receptor (FcεRI) on immune cells. Developing such therapies requires a multifaceted approach, involving antibody discovery, purification, characterization, and pharmacokinetic/pharmacodynamic (PK/PD) analysis to ensure both safety and efficacy. Scientists are now refining these techniques to create more targeted and long-lasting anti-IgE therapies. The Protective Power of IgA While IgE has long been recognized as the villain in allergic responses, another antibody—Immunoglobulin A (IgA)—is gaining attention for its protective role. IgA is the most abundant antibody in mucosal surfaces, such as those lining the respiratory and digestive tracts. Its primary function is to block the entry of allergens and pathogens, acting as a first line of immune defense. Interestingly, individuals with higher levels of mucosal IgA often exhibit a lower risk of developing allergic diseases. IgA has also been shown to regulate inflammation and modulate immune cell activity, contributing to a more balanced immune response. Given these benefits, scientists are now investigating how IgA could be harnessed therapeutically. This includes strategies to enhance IgA production or design therapeutic IgA antibodies that could mimic its natural protective functions. These approaches could complement existing anti-IgE therapies or provide alternative options for individuals who do not respond well to current treatments. Beyond Allergies: A Broader Potential Although much of the current research on non-IgG antibodies focuses on allergy treatment, the applications are not limited to this area. Non-IgG antibodies, including IgA and others like IgM or engineered isotypes, are being studied for their roles in combating infectious diseases, cancer, and chronic inflammation. Developing these antibodies requires advanced technologies such as phage display, a method that allows scientists to rapidly identify antibodies with high specificity and affinity for their targets. Through platforms that combine high-throughput screening with molecular engineering, researchers can now create tailored antibodies designed to interact with immune pathways in very precise ways. This technological progress is accelerating the development of novel therapeutics across a wide spectrum of diseases. By leveraging the distinct properties of each antibody class, scientists are expanding the toolbox for immunotherapy, offering more personalized and effective treatment options. Conclusion As allergic diseases continue to rise globally, the need for more effective and long-lasting therapies becomes increasingly urgent. Non-IgG therapeutic antibodies—particularly those targeting IgE and harnessing the protective qualities of IgA—represent a promising frontier in allergen immunotherapy. By focusing on the immune system's underlying mechanisms, these innovative approaches aim not just to control allergy symptoms, but to alter the course of the disease itself. With continued research and collaboration across the fields of immunology, molecular biology, and therapeutic development, the future of allergy treatment looks increasingly hopeful—and smarter than ever. https://non-igg-ab.creative-biolabs.com/allergen-immunotherapy-ait.htm
-
-
Acesso Biologics is a leading specialist in amniotic membrane products for regenerative medicine and advanced wound healing. Their clinically proven offerings harness the natural therapeutic benefits of the amniotic membrane—rich in growth factors, extracellular matrix, and anti-inflammatory agents—to promote rapid tissue repair and reduce scarring. Designed for versatile clinical use in wound care, orthopedics, ophthalmology, and surgical repair, Acesso Biologics delivers high standards of purity, safety, and consistency. Trusted by healthcare professionals, their products support improved patient recovery outcomes and drive innovation in biologic treatments. #AmnioticMembrane #RegenerativeMedicine #WoundHealing @AcessoBiologics https://www.acessobio.com/products/
Copyright 2019 © P-tweets Refunds